Cargando…

Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway

PURPOSE: Anlotinib protects against carcinogenesis through the induction of autophagy and apoptosis. The current study evaluated the role and molecular mechanisms of anlotinib in glioblastoma, and the effects of anlotinib in combination with temozolomide (TMZ). METHODS: Cell Counting Kit-8 and colon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Peng, Wang, Handong, Pan, Hao, Chen, Jiakai, Deng, Chulei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807469/ https://www.ncbi.nlm.nih.gov/pubmed/34997858 http://dx.doi.org/10.1007/s00280-021-04380-5

Ejemplares similares

Retrospective Study of the Safety and Efficacy of Anlotinib Combined With Dose-Dense Temozolomide in Patients With Recurrent Glioblastoma
por: She, Lei, et al.
Publicado: (2021)

Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation
por: Hou, Zhiwei, et al.
Publicado: (2023)

LncRNA NEAT1 Enhances Glioma Progression via Regulating the miR-128-3p/ITGA5 Axis
por: Chen, Jiakai, et al.
Publicado: (2021)

Gossypol Suppresses Growth of Temozolomide-Resistant Glioblastoma Tumor Spheres
por: Kim, Hee Yeon, et al.
Publicado: (2019)

VSIG4 Silencing Inhibits Glioblastoma Growth by Regulating the JAK2/STAT3 Pathway
por: Zheng, Congying, et al.
Publicado: (2023)

Anlotinib Alone or in Combination With Temozolomide in the Treatment of Recurrent High-Grade Glioma: A Retrospective Analysis
por: Yang, Qunying, et al.
Publicado: (2021)

Tanshinone I inhibits the growth and metastasis of osteosarcoma via suppressing JAK/STAT3 signalling pathway
por: Wang, Weiguo, et al.
Publicado: (2019)

The Role of Natural Products as Inhibitors of JAK/STAT Signaling Pathways in Glioblastoma Treatment
por: Fahmideh, Hanieh, et al.
Publicado: (2022)

Anlotinib combined with temozolomide for the treatment of patients with diffuse midline glioma: a case report and literature review
por: Feng, Yiping, et al.
Publicado: (2022)

The Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma
por: Ou, Alexander, et al.
Publicado: (2021)

HOXD‐AS2‐STAT3 feedback loop attenuates sensitivity to temozolomide in glioblastoma
por: Zhang, Zuo‐Xin, et al.
Publicado: (2023)

Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway
por: Chen, Liwen, et al.
Publicado: (2018)

The Drosophila JAK-STAT pathway
por: Zeidler, Martin P, et al.
Publicado: (2013)

Evolution of the JAK-STAT pathway
por: Liongue, Clifford, et al.
Publicado: (2013)

The JAK-STAT pathway at 20
por: Darnell, Jr., James E.
Publicado: (2012)

Suppression of Autoimmune Arthritis by Small Molecule Inhibitors of the JAK/STAT Pathway
por: Malemud, Charles J.
Publicado: (2010)

Repurposing Penfluridol in Combination with Temozolomide for the Treatment of Glioblastoma
por: Kim, Hyungsin, et al.
Publicado: (2019)

Liensinine Inhibits Osteosarcoma Growth by ROS-Mediated Suppression of the JAK2/STAT3 Signaling Pathway
por: Jia, Fei, et al.
Publicado: (2022)

TROP2 promotes the proliferation and metastasis of glioblastoma cells by activating the JAK2/STAT3 signaling pathway
por: Hou, Jianbing, et al.
Publicado: (2019)

Dihydroartemisinin initiates ferroptosis in glioblastoma through GPX4 inhibition
por: Yi, Renxin, et al.
Publicado: (2020)

An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
por: Lensing, Maddison, et al.
Publicado: (2022)

The effect of valproic acid on intrinsic, extrinsic, and JAK/STAT pathways in neuroblastoma and glioblastoma cell lines
por: Sanaei, Masumeh, et al.
Publicado: (2022)

Dihydrotanshinone Inhibits Hepatocellular Carcinoma by Suppressing the JAK2/STAT3 Pathway
por: Hu, Xue, et al.
Publicado: (2021)

JAK-STAT pathway and myogenic differentiation
por: Jang, You-Na, et al.
Publicado: (2013)

JAK-STAT Signalling Pathway in Cancer
por: Brooks, Andrew J., et al.
Publicado: (2020)

JAK-STAT pathway inhibitors in dermatology()
por: Miot, Hélio Amante, et al.
Publicado: (2023)

Morphine in Combination with Ketamine Improves Cervical Cancer Pain and Suppresses Immune Function via the JAK3/STAT5 Pathway
por: Jiang, Yurong, et al.
Publicado: (2022)

Suppressing TRAP1 sensitizes glioblastoma multiforme cells to temozolomide
por: Wang, Nan, et al.
Publicado: (2021)

EZH2 inhibition suppresses bladder cancer cell growth and metastasis via the JAK2/STAT3 signaling pathway
por: Chen, Zhiyuan, et al.
Publicado: (2019)

NR1D1 suppressed the growth of ovarian cancer by abrogating the JAK/STAT3 signaling pathway
por: Wang, Huailin, et al.
Publicado: (2021)

Combined Effects of Doxorubicin and Temozolomide in Cultured Glioblastoma Cells
por: BALOI, CARINA, et al.
Publicado: (2022)

Integrins and p53 pathways in glioblastoma resistance to temozolomide
por: Martin, Sophie, et al.
Publicado: (2012)

Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway
por: Chung, Shin-Yi, et al.
Publicado: (2021)

The significance of microRNA-184 on JAK2/STAT3 signaling pathway in the formation mechanism of glioblastoma
por: ZHANG, XUEKUI, et al.
Publicado: (2015)

Anlotinib suppresses lung adenocarcinoma growth via inhibiting FASN-mediated lipid metabolism
por: Shen, Juan, et al.
Publicado: (2022)

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
por: Boyle, D L, et al.
Publicado: (2015)

Osteosarcoma cell proliferation suppression via SHP-2-mediated inactivation of the JAK/STAT3 pathway by tubocapsenolide A
por: Zhu, Dongrong, et al.
Publicado: (2021)

Transcriptional regulation by STAT1 and STAT2 in the interferon JAK-STAT pathway
por: Au-Yeung, Nancy, et al.
Publicado: (2013)

Pretreatment with Eupatilin Attenuates Inflammation and Coagulation in Sepsis by Suppressing JAK2/STAT3 Signaling Pathway
por: Lu, Yilun, et al.
Publicado: (2023)

Temozolomide suppresses MYC via activation of TAp63 to inhibit progression of human glioblastoma
por: Yamaki, Tomohiro, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_6kqtkumsci4h2vs1esp1pai9qi